Autoimmune Market Research Reports & Industry Analysis
Classification of autoimmune disorders is still somewhat controversial, but the following criteria is generally accepted: Direct evidence from transfer of pathogenic antibody or pathogenic T cells, indirect evidence based on reproduction of the autoimmune disease in experimental animals, and circumstantial evidence from clinical clues
Arthritis is among the most common autoimmune disorders. Arthritis is joint inflammation The major complaint by individuals who have arthritis is joint pain. Pain is often a constant and may be localized to the joint affected. There are over one hundred forms different forms The most common form, osteoarthritis (degenerative joint disease) is a result of trauma to the joint, infection of the joint, or age. Other arthritis forms are rheumatoid arthritis, psoriatic arthritis, and related autoimmune diseases. Septic arthritis is caused by joint infection. Treatment options vary depending on the type of arthritis and include physical therapy, exercise and weight control, bracing, medications. Surgery may be required in some changes.
Autoimmune Industry Research & Market Reports
-
The 2025-2030 World Outlook for Primary Immunodeficiency
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Primary Immunodeficiency Diseases
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Subcutaneous Immunoglobulins
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Guillain-Barre Syndrome Therapeutics
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Systemic Lupus Erythematosus (SLE) Drugs
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2025-2030 World Outlook for Systematic Lupus Erythematosus Treatments
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Autoimmune Disorder Diagnostics
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Immunoglobulins
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2025-2030 World Outlook for Anti-Inflammatory Lupus Drugs
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Autoimmune Disease Diagnostic Consumables and Assay Kits
... estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. ... Read More
-
The 2025-2030 World Outlook for Autoimmune Disease Therapeutics
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Systemic Lupus Erythematosus
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Autoimmune Treatments
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Autoimmune Disease Diagnostics
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Progressive Multifocal Leukoencephalopathy Treatments
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Intravenous Immunoglobulins
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Primary Immunodeficiency Disease Tests
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Plasma Fractionation of Intravenous Immunoglobulins
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2025-2030 World Outlook for Monocyte Activation Test Kits
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Anti-Inflammatory Autoimmune Disease Therapeutics
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Lupus Therapeutics
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
Cell Therapy Market Report by Cell Type (Stem Cell, Non-stem Cell), Therapy Type (Autologous, Allogeneic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), End User (Hospitals and Clinics, Academic and Research Institutes), and Region 2024-2032
... Region 2024-2032 The global cell therapy market size reached US$ 13.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 50.5 Billion by 2032, exhibiting a growth rate (CAGR) of 15.28% ... Read More
-
Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Indication (Auto-Immune Diseases, Blood Disorders, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032
... Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032 The global biosimilar market size reached US$ 21.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 164.5 Billion by 2032, exhibiting ... Read More
-
In Vitro Diagnostics Market Report by Test Type (Clinical Chemistry, Molecular Diagnostics, Immunodiagnostics, Hematology, and Others), Product (Reagents and Kits, Instruments), Usability (Disposable IVD Devices, Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others), End User (Hospitals Laboratories, Clinical Laboratories, Point-of-care Testing Centers, Academic Institutes, Patients, and Others), and Region 2024-2032
... Disease, Nephrology, and Others), End User (Hospitals Laboratories, Clinical Laboratories, Point-of-care Testing Centers, Academic Institutes, Patients, and Others), and Region 2024-2032 The global in vitro diagnostics market size reached US$ 110.9 Billion in 2023. Looking ... Read More
-
Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition): Analysis By Antibody Source (Humanized, Fully Human, Chimeric, Other Sources), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)
... has released a research report titled “Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)” which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market ... Read More
Research Assistance
